Tenderwize
Zurück zur Suche

Open-house discount agreement for Levothyroxin-Natrium

AOK Bayern - Die Gesundheitskasse·München, Germany·Deadline Mar 03, 2028 · 553 days left·Open·Supplies·Framework
Registrieren zum SpeichernOpen documents
Originaltitel der Bekanntmachung

Germany – Pharmaceutical products – Open house Arzneimittelrabattverträge Levothyroxin-Natrium, ATC H03AA01

58/100

Opportunity Score

Needs reviewMedium complexity
SuppliesFrameworkOpen
Warum diese Bewertung?

Chance

58 / 100

Komplexität

54 / 100

Risikofaktoren

The buyer explicitly states that this is an open-house model and not a normal open procedure; standard procurement assu...

Contract documents must be submitted through the communication area in the DTVP portal, not through the offer area; mis...

Tiefe Portfolioanalyse

Tiefe Analyse der Unternehmenspassung

Verwendet:

  • Description
  • Industries & Services
  • Capabilities
  • Market & Experience
  • Certifications

Überblick

Moderate opportunity

Wichtige Fakten

  • Framework procurement
  • Supplies contract
  • 1 lot
  • Duration until Apr 2028
  • Non-exclusive supply/discount agreement for Levothyroxin-Natrium, ATC H03AA01.
  • Open-house accession model with identical, pre-set contract terms for qualifying pharmaceutical companies.
Vollständige Zusammenfassung anzeigen

This is an open-house supply arrangement for pharmaceutical discount agreements on Levothyroxin-Natrium (ATC H03AA01) with AOK Bayern. It is not a competitive open procedure in the usual sense: the buyer states that all interested pharmaceutical companies meeting the stated suitability requirement can join on identical, non-negotiable terms. The contract term starts earliest on 2026-05-01 and ends on 2028-04-30, with a final contract entry deadline of 2028-03-03 11:00. No estimated contract value is provided.

Risiken

The buyer explicitly states that this is an open-house model and not a normal open procedure; standard procurement assu...

Contract documents must be submitted through the communication area in the DTVP portal, not through the offer area; mis...

Analyse kann unvollständig sein

Nur ein Teil der Vergabeunterlagen wurde analysiert. Weitere Anforderungen, Zertifikate oder Einreichungsdokumente können in den übrigen Unterlagen enthalten sein.

Wichtige Anforderungen

Technical

  • Contract and annex 'Festlegung der vertragsgegenständlichen Arzneimittel' must be completed and signed.

Eligibility

  • Only pharmaceutical companies are eligible as potential contract partners.

Administrative

  • Signed declaration of reliability must be submitted.

Zuschlagskriterien

Lot 1

No lot-specific award criteria are stated; this appears to be an open-house accession model rather than a scored award process.

Auftraggeber

Ort

München, DEU

Website

www.aok.de

Auftraggeberprofil

Profil öffnen

Kennung

DE811695320

Tätigkeit

Health

Lose (1)

LOT-0001

Open-house discount agreement for Levothyroxin-Natrium

Single lot covering non-exclusive open-house discount agreements for the pharmaceutical product Levothyroxin-Natrium (ATC H03AA01). The buyer indicates that contracts are identical, non-individually negotiable, and open to all interested pharmaceutical companies meeting the stated suitability requirement. Performance is in Germany, Bayern (DE212).

SuppliesFrameworkEU fundedElectronic submission

Ort

DE212, Germany

Dauer

Apr 2026 - Apr 2028

Kategorie

Pharmaceutical products

Zuschlagskriterien

No lot-specific award criteria are stated; this appears to be an open-house accession model rather than a scored award process.

Frist

Deadline Mar 03, 2028

Vergabedetails

Veröffentlichungsdatum
15 Mar 2026
Sprachen
German

Referenzmetadaten

Rechtsgrundlage
32014L0024

Referenz-IDs

Ausschreibungs-ID
180221-2026

Dokumente (2)

Vergabedokument 1Einreichungsportal 1

Ähnliche Ausschreibungen

Bulgaria – Pharmaceutical products – Динамична система за покупки за доставка на лекарствени продукти за Медицински институт на МВР

Jul 9

Germany – Pharmaceutical products – Abschluss nicht exkl. Arzneimittel-Rabattvereinb. nach § 130a Abs. 8 SGB V im Wege eines Open-House-Modells über Arzneimittel mit dem Handelsnamen Oralair(R) (ATC-Code nach WHO: V01AA02)

Aug 31

Germany – Pharmaceutical products – Abschluss nicht exkl. Arzneimittel-Rabattvereinb. nach § 130a Abs. 8 SGB V im Wege eines Open-House-Modells zum Wirkstoff Ipratropiumbromid (ATC-Code nach WHO: R03BB01)

Sep 30

Denmark – Pharmaceutical products – Amgros 2027 1.1170.a

Sep 3

Germany – Pharmaceutical products – Abschluss nicht exkl. Arzneimittel-Rabattvereinb. nach § 130a Abs. 8 SGB V im Wege eines Open-House-Modells über Arzneimittel mit dem Handelsnamen Orylmyte(R) (ATC-Code nach WHO: V01AA03)

Aug 31

Germany – Pharmaceutical products – Open House Biologika Rabattverträge 2026 - 27 - Follitropin delta

Aug 30